Panelists discuss how biomarkers of type 2 inflammation, such as blood eosinophils, serum IgE, and fractional exhaled nitric oxide, can aid in diagnosing and monitoring type 2 inflammatory diseases as well as in predicting treatment response.
What tests or biomarkers are used to determine if a patient’s disease may be caused by type 2 inflammation? How does this information aid your medication selection process?